- Home
- PAYO vs HCM Comparison
PAYO vs HCM Comparison
Compare PAYO & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- HCM
- Stock Information
- Founded
- PAYO 2005
- HCM 2000
- Country
- PAYO United States
- HCM Hong Kong
- Employees
- PAYO N/A
- HCM N/A
- Industry
- PAYO EDP Services
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- HCM Health Care
- Exchange
- PAYO Nasdaq
- HCM Nasdaq
- Market Cap
- PAYO 2.5B
- HCM 2.5B
- IPO Year
- PAYO N/A
- HCM N/A
- Fundamental
- Price
- PAYO $6.72
- HCM $17.78
- Analyst Decision
- PAYO Strong Buy
- HCM Buy
- Analyst Count
- PAYO 8
- HCM 2
- Target Price
- PAYO $9.81
- HCM $23.50
- AVG Volume (30 Days)
- PAYO 2.5M
- HCM 58.9K
- Earning Date
- PAYO 08-06-2025
- HCM 08-07-2025
- Dividend Yield
- PAYO N/A
- HCM N/A
- EPS Growth
- PAYO N/A
- HCM N/A
- EPS
- PAYO 0.28
- HCM 0.04
- Revenue
- PAYO $996,150,000.00
- HCM $630,201,000.00
- Revenue This Year
- PAYO $4.32
- HCM $14.86
- Revenue Next Year
- PAYO $5.59
- HCM $19.54
- P/E Ratio
- PAYO $24.02
- HCM $80.74
- Revenue Growth
- PAYO 14.86
- HCM N/A
- 52 Week Low
- PAYO $5.03
- HCM $11.51
- 52 Week High
- PAYO $11.29
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- PAYO 47.59
- HCM 68.32
- Support Level
- PAYO $6.74
- HCM $17.36
- Resistance Level
- PAYO $6.97
- HCM $17.97
- Average True Range (ATR)
- PAYO 0.22
- HCM 0.33
- MACD
- PAYO 0.00
- HCM 0.13
- Stochastic Oscillator
- PAYO 46.55
- HCM 91.51
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.